Symbols / NKTX
NKTX Chart
About
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 178.28M |
| Enterprise Value | -41.62M | Income | -102.61M | Sales | — |
| Book/sh | 4.76 | Cash/sh | 3.98 | Dividend Yield | — |
| Payout | 0.00% | Employees | 105 | IPO | — |
| P/E | — | Forward P/E | -1.91 | PEG | — |
| P/S | — | P/B | 0.53 | P/C | — |
| EV/EBITDA | 0.39 | EV/Sales | — | Quick Ratio | 14.98 |
| Current Ratio | 15.23 | Debt/Eq | 22.68 | LT Debt/Eq | — |
| EPS (ttm) | -1.49 | EPS next Y | -1.31 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 | ROA | -15.14% |
| ROE | -26.69% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 71.03M |
| Shs Float | 53.15M | Short Float | 12.19% | Short Ratio | 7.48 |
| Short Interest | — | 52W High | 2.74 | 52W Low | 1.31 |
| Beta | 0.52 | Avg Volume | 733.33K | Volume | 1.29M |
| Target Price | $14.00 | Recom | Strong_buy | Prev Close | $2.31 |
| Price | $2.51 | Change | 8.66% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$14.00
Mean price target
2. Current target
$2.51
Latest analyst target
3. DCF / Fair value
$-14.58
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.51
Low
$8.00
High
$25.00
Mean
$14.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-11 | main | Stifel | Buy → Buy | $11 |
| 2025-08-14 | main | Stifel | Buy → Buy | $12 |
| 2025-08-13 | reit | Needham | Buy → Buy | $10 |
| 2025-06-10 | main | Mizuho | Outperform → Outperform | $14 |
| 2025-05-15 | main | Needham | Buy → Buy | $10 |
| 2025-05-15 | down | William Blair | Outperform → Market Perform | — |
| 2025-04-09 | reit | Needham | Buy → Buy | $11 |
| 2025-03-27 | main | Stifel | Buy → Buy | $14 |
| 2025-03-27 | reit | Needham | Buy → Buy | $11 |
| 2025-03-27 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-11-21 | main | Mizuho | Outperform → Outperform | $16 |
| 2024-11-11 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-11-08 | main | Needham | Buy → Buy | $11 |
| 2024-08-15 | main | HC Wainwright & Co. | Buy → Buy | $22 |
| 2024-08-14 | reit | Needham | Buy → Buy | $13 |
| 2024-08-14 | up | Raymond James | Outperform → Strong Buy | $16 |
| 2024-07-24 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-06-28 | reit | Needham | Buy → Buy | $13 |
| 2024-06-27 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-05-13 | main | HC Wainwright & Co. | Buy → Buy | $23 |
- We Think Nkarta (NASDAQ:NKTX) Needs To Drive Business Growth Carefully - Yahoo Finance hu, 04 Dec 2025 08
- Nkarta CEO Hastings sells $53,915 in NKTX stock - Investing.com ue, 20 Jan 2026 08
- Is Nkarta (NASDAQ:NKTX) In A Good Position To Deliver On Growth Plans? - simplywall.st Sat, 01 Nov 2025 07
- Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason - Seeking Alpha Sat, 22 Nov 2025 08
- Insider Sale: Chief Executive Officer of $NKTX Sells 26,046 Shares - Quiver Quantitative ue, 20 Jan 2026 08
- Is NKTX stock a top pick in earnings season - Weekly Volume Report & Risk Controlled Daily Trade Plans - mfd.ru Fri, 20 Feb 2026 13
- Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025 - Seeking Alpha ue, 22 Jul 2025 07
- Stock Analysis: Whats the fair value of NKTX stock - Earnings Recap Summary & Fast Entry Momentum Alerts - baoquankhu1.vn Wed, 18 Feb 2026 10
- Nkarta (NKTX) Upgraded to Buy: Here's Why - Yahoo Finance Mon, 14 Apr 2025 07
- Nkarta (NKTX) president Nadir sells $11,693 in shares - Investing.com ue, 20 Jan 2026 08
- Nkarta, Inc. to Present Clinical Data for NKX019 Therapy at ACR Convergence 2025 Meeting - Quiver Quantitative Wed, 22 Oct 2025 07
- Is NKTX stock a value trap - Dollar Strength & Entry Point Confirmation Signals - mfd.ru Sat, 21 Feb 2026 03
- Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance Mon, 19 May 2025 07
- Nkarta (NKTX) - Zacks Investment Research Wed, 15 Jul 2020 10
- Stifel lowers Nkarta stock price target to $11 from $12, keeps Buy rating - Investing.com ue, 11 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 26046 | 53915 | — | Sale at price 2.07 per share. | HASTINGS PAUL J | Chief Executive Officer | — | 2026-01-15 00:00:00 | D |
| 1 | 5649 | 11693 | — | Sale at price 2.07 per share. | MAHMOOD NADIR AHMEDUDDIN | President | — | 2026-01-15 00:00:00 | D |
| 2 | 94000 | — | — | Stock Award(Grant) at price 0.00 per share. | HASTINGS PAUL J | Chief Executive Officer | — | 2026-01-06 00:00:00 | D |
| 3 | 80000 | — | — | Stock Award(Grant) at price 0.00 per share. | MAHMOOD NADIR AHMEDUDDIN | President | — | 2026-01-06 00:00:00 | D |
| 4 | 70000 | — | — | Stock Award(Grant) at price 0.00 per share. | ROSE SHAWN MARSHALL | Officer | — | 2026-01-06 00:00:00 | D |
| 5 | 1790 | 3204 | — | Sale at price 1.79 per share. | HASTINGS PAUL J | Chief Executive Officer | — | 2025-06-18 00:00:00 | D |
| 6 | 17378 | 38232 | — | Sale at price 2.20 per share. | HASTINGS PAUL J | Chief Executive Officer | — | 2025-01-15 00:00:00 | D |
| 7 | 9584 | 21085 | — | Sale at price 2.20 per share. | HAGER ALICIA J | Officer | — | 2025-01-15 00:00:00 | D |
| 8 | 7447 | 16383 | — | Sale at price 2.20 per share. | BRANDENBERGER RALPH ERIK | Chief Technology Officer | — | 2025-01-15 00:00:00 | D |
| 9 | 8638 | 19004 | — | Sale at price 2.20 per share. | SHOOK DAVID M.D. | Officer | — | 2025-01-15 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -119.04M | -125.78M | -116.32M | -84.67M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -108.79M | -117.50M | -113.84M | -86.08M |
| ReconciledDepreciation | 9.15M | 5.87M | 2.64M | 1.76M |
| EBITDA | -119.04M | -125.78M | -116.32M | -84.67M |
| EBIT | -128.19M | -131.65M | -118.95M | -86.43M |
| NetInterestIncome | 19.32M | 14.11M | 5.59M | 370.00K |
| InterestIncome | 19.32M | 14.11M | 5.59M | 370.00K |
| NormalizedIncome | -108.79M | -117.50M | -113.84M | -86.08M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -108.79M | -117.50M | -113.84M | -86.08M |
| TotalExpenses | 128.19M | 131.65M | 118.95M | 86.43M |
| TotalOperatingIncomeAsReported | -128.19M | -131.65M | -118.95M | -86.43M |
| DilutedAverageShares | 67.87M | 49.01M | 43.63M | 32.86M |
| BasicAverageShares | 67.87M | 49.01M | 43.63M | 32.86M |
| DilutedEPS | -1.60 | -2.40 | -2.61 | -2.62 |
| BasicEPS | -1.60 | -2.40 | -2.61 | -2.62 |
| DilutedNIAvailtoComStockholders | -108.79M | -117.50M | -113.84M | -86.08M |
| NetIncomeCommonStockholders | -108.79M | -117.50M | -113.84M | -86.08M |
| NetIncome | -108.79M | -117.50M | -113.84M | -86.08M |
| NetIncomeIncludingNoncontrollingInterests | -108.79M | -117.50M | -113.84M | -86.08M |
| NetIncomeContinuousOperations | -108.79M | -117.50M | -113.84M | -86.08M |
| PretaxIncome | -108.79M | -117.50M | -113.84M | -86.08M |
| OtherIncomeExpense | 87.00K | 42.00K | -470.00K | -16.00K |
| OtherNonOperatingIncomeExpenses | 87.00K | 42.00K | -470.00K | -16.00K |
| NetNonOperatingInterestIncomeExpense | 19.32M | 14.11M | 5.59M | 370.00K |
| InterestIncomeNonOperating | 19.32M | 14.11M | 5.59M | 370.00K |
| OperatingIncome | -128.19M | -131.65M | -118.95M | -86.43M |
| OperatingExpense | 128.19M | 131.65M | 118.95M | 86.43M |
| ResearchAndDevelopment | 96.74M | 96.77M | 90.90M | 63.41M |
| SellingGeneralAndAdministration | 31.45M | 34.88M | 28.06M | 23.02M |
| GeneralAndAdministrativeExpense | 31.45M | 34.88M | 28.06M | 23.02M |
| OtherGandA | 31.45M | 34.88M | 28.06M | 23.02M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 70.65M | 49.18M | 48.88M | 32.97M |
| ShareIssued | 70.65M | 49.18M | 48.88M | 32.97M |
| TotalDebt | 80.27M | 88.34M | 82.93M | 12.46M |
| TangibleBookValue | 407.98M | 273.29M | 372.21M | 250.97M |
| InvestedCapital | 407.98M | 273.29M | 372.21M | 250.97M |
| WorkingCapital | 254.42M | 229.74M | 338.64M | 232.84M |
| NetTangibleAssets | 407.98M | 273.29M | 372.21M | 250.97M |
| CapitalLeaseObligations | 80.27M | 88.34M | 82.93M | 12.46M |
| CommonStockEquity | 407.98M | 273.29M | 372.21M | 250.97M |
| TotalCapitalization | 407.98M | 273.29M | 372.21M | 250.97M |
| TotalEquityGrossMinorityInterest | 407.98M | 273.29M | 372.21M | 250.97M |
| StockholdersEquity | 407.98M | 273.29M | 372.21M | 250.97M |
| GainsLossesNotAffectingRetainedEarnings | 674.00K | 8.00K | -679.00K | -150.00K |
| OtherEquityAdjustments | 674.00K | 8.00K | -679.00K | -150.00K |
| RetainedEarnings | -544.22M | -435.43M | -317.93M | -204.10M |
| AdditionalPaidInCapital | 951.52M | 708.71M | 690.81M | 455.21M |
| CapitalStock | 7.00K | 5.00K | 5.00K | 3.00K |
| CommonStock | 7.00K | 5.00K | 5.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 93.23M | 105.60M | 100.73M | 22.94M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 74.31M | 82.27M | 78.69M | 9.99M |
| OtherNonCurrentLiabilities | 87.00K | 18.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 74.22M | 82.27M | 78.69M | 9.97M |
| LongTermCapitalLeaseObligation | 74.22M | 82.27M | 78.69M | 9.97M |
| CurrentLiabilities | 18.92M | 23.33M | 22.05M | 12.94M |
| CurrentDebtAndCapitalLeaseObligation | 6.05M | 6.07M | 4.25M | 2.48M |
| CurrentCapitalLeaseObligation | 6.05M | 6.07M | 4.25M | 2.48M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 7.92M | 6.72M | 6.69M | 5.45M |
| PayablesAndAccruedExpenses | 4.95M | 10.54M | 11.11M | 5.01M |
| CurrentAccruedExpenses | 4.31M | 6.87M | 9.35M | 3.89M |
| Payables | 638.00K | 3.67M | 1.76M | 1.11M |
| AccountsPayable | 638.00K | 3.67M | 1.76M | 1.11M |
| TotalAssets | 501.20M | 378.88M | 472.94M | 273.90M |
| TotalNonCurrentAssets | 227.87M | 125.81M | 112.25M | 28.12M |
| OtherNonCurrentAssets | 6.80M | 6.54M | 4.59M | 3.59M |
| InvestmentsAndAdvances | 110.39M | 0.00 | ||
| InvestmentinFinancialAssets | 110.39M | 0.00 | ||
| AvailableForSaleSecurities | 110.39M | |||
| NetPPE | 110.67M | 119.28M | 107.66M | 24.53M |
| AccumulatedDepreciation | -20.84M | -11.69M | -5.82M | -3.19M |
| GrossPPE | 131.52M | 130.97M | 113.48M | 27.72M |
| Leases | 66.62M | 66.62M | 4.40M | 3.46M |
| ConstructionInProgress | 10.82M | 8.95M | 49.66M | 2.27M |
| OtherProperties | 52.93M | 54.25M | 58.65M | 21.31M |
| MachineryFurnitureEquipment | 1.15M | 1.15M | 775.00K | 674.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 273.34M | 253.07M | 360.69M | 245.78M |
| OtherCurrentAssets | 2.73M | 1.62M | 2.93M | 3.15M |
| PrepaidAssets | 3.25M | 3.26M | 5.62M | 4.54M |
| CashCashEquivalentsAndShortTermInvestments | 267.35M | 248.19M | 352.14M | 238.09M |
| OtherShortTermInvestments | 239.48M | 217.15M | 314.65M | 177.27M |
| CashAndCashEquivalents | 27.87M | 31.04M | 37.49M | 60.82M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -104.11M | -114.31M | -104.11M | -72.95M |
| IssuanceOfCapitalStock | 225.07M | 0.00 | 217.17M | 0.00 |
| CapitalExpenditure | -4.41M | -28.15M | -47.11M | -5.03M |
| EndCashPosition | 30.62M | 33.78M | 40.24M | 62.91M |
| BeginningCashPosition | 33.78M | 40.24M | 62.91M | 97.11M |
| ChangesInCash | -3.17M | -6.45M | -22.68M | -34.19M |
| FinancingCashFlow | 226.08M | 691.00K | 219.01M | 1.20M |
| CashFlowFromContinuingFinancingActivities | 226.08M | 691.00K | 219.01M | 1.20M |
| NetOtherFinancingCharges | -277.00K | |||
| ProceedsFromStockOptionExercised | 1.01M | 691.00K | 1.84M | 1.48M |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 225.07M | 0.00 | 217.17M | 0.00 |
| CommonStockIssuance | 225.07M | 0.00 | 217.17M | 0.00 |
| InvestingCashFlow | -129.56M | 79.02M | -184.69M | 32.53M |
| CashFlowFromContinuingInvestingActivities | -129.56M | 79.02M | -184.69M | 32.53M |
| NetInvestmentPurchaseAndSale | -125.15M | 107.16M | -137.58M | 37.56M |
| SaleOfInvestment | 281.23M | 367.39M | 248.31M | 264.84M |
| PurchaseOfInvestment | -406.38M | -260.23M | -385.89M | -227.28M |
| NetPPEPurchaseAndSale | -4.41M | -28.15M | -47.11M | -5.03M |
| PurchaseOfPPE | -4.41M | -28.15M | -47.11M | -5.03M |
| OperatingCashFlow | -99.70M | -86.16M | -57.00M | -67.93M |
| CashFlowFromContinuingOperatingActivities | -99.70M | -86.16M | -57.00M | -67.93M |
| ChangeInWorkingCapital | -12.16M | 10.93M | 33.74M | -1.64M |
| ChangeInOtherCurrentLiabilities | -6.33M | 4.99M | 32.47M | |
| ChangeInPayablesAndAccruedExpense | -4.47M | 4.22M | 2.76M | 2.79M |
| ChangeInPayable | -4.47M | 4.22M | 2.76M | 2.79M |
| ChangeInAccountPayable | -4.47M | 4.22M | 2.76M | 2.79M |
| ChangeInPrepaidAssets | -1.36M | 1.72M | -1.49M | -4.43M |
| OtherNonCashItems | 2.29M | 2.22M | 3.94M | 337.00K |
| StockBasedCompensation | 16.73M | 17.20M | 16.86M | 14.46M |
| AssetImpairmentCharge | 0.00 | 4.10M | 0.00 | |
| AmortizationOfSecurities | -6.91M | -8.94M | -818.00K | 3.24M |
| DepreciationAmortizationDepletion | 9.15M | 5.87M | 2.64M | 1.76M |
| DepreciationAndAmortization | 9.15M | 5.87M | 2.64M | 1.76M |
| OperatingGainsLosses | -34.00K | 490.00K | ||
| GainLossOnInvestmentSecurities | -34.00K | 490.00K | ||
| NetIncomeFromContinuingOperations | -108.79M | -117.50M | -113.84M | -86.08M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for NKTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|